Excessive glial activation, with overproduction of cytokines and oxidative stress products, is detrimental and a hallmark of neurodegenerative disease pathology. Suppression of glial activation is a potential therapeutic approach, and protein kinases are targets of some antiinflammatory drugs. To address an unmet need for selective inhibitors of glial activation, we developed a novel 3-amino-6-phenylpyridazine derivative that selectively blocks increased IL-1β, iNOS, and NO production by activated glia, without inhibition of potentially beneficial glial functions.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Medicinal Chemistry|
|State||Published - Jan 31 2002|
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery